Celldex Therapeutics, Inc. (CLDX)
USD 15.9
(-7.29%)
USD 15.9
(-7.29%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -32.27 Million USD | -27.08% |
| 2022 | -25.39 Million USD | 29.65% |
| 2021 | -36.1 Million USD | 10.54% |
| 2020 | -40.35 Million USD | -432.74% |
| 2019 | -7.57 Million USD | 61.71% |
| 2018 | -19.78 Million USD | 41.33% |
| 2017 | -33.72 Million USD | 20.58% |
| 2016 | -42.46 Million USD | 37.27% |
| 2015 | -67.69 Million USD | -166.2% |
| 2014 | -25.42 Million USD | 84.99% |
| 2013 | -169.4 Million USD | -1149.37% |
| 2012 | -13.55 Million USD | -491.43% |
| 2011 | 3.46 Million USD | 130.69% |
| 2010 | -11.28 Million USD | 73.85% |
| 2009 | -43.16 Million USD | 0.25% |
| 2008 | -43.27 Million USD | -312.5% |
| 2007 | -10.48 Million USD | 71.08% |
| 2006 | -36.26 Million USD | -56.32% |
| 2005 | -23.2 Million USD | 21.72% |
| 2004 | -29.64 Million USD | -46.37% |
| 2003 | -20.25 Million USD | 19.22% |
| 2002 | -25.07 Million USD | 41.24% |
| 2001 | -42.66 Million USD | 14.5% |
| 2000 | -49.9 Million USD | -282.22% |
| 1999 | -13.05 Million USD | -78.85% |
| 1998 | -7.3 Million USD | -52.08% |
| 1997 | -4.8 Million USD | 61.9% |
| 1996 | -12.6 Million USD | -4.13% |
| 1995 | -12.1 Million USD | -70.42% |
| 1994 | -7.1 Million USD | 74.46% |
| 1993 | -27.8 Million USD | -742.42% |
| 1992 | -3.3 Million USD | 62.07% |
| 1991 | -8.7 Million USD | 23.01% |
| 1990 | -11.3 Million USD | -17.71% |
| 1989 | -9.6 Million USD | 11.11% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -40.35 Million USD | 64.28% |
| 2024 Q1 | -112.96 Million USD | -250.03% |
| 2023 Q3 | -18.28 Million USD | 26.76% |
| 2023 Q2 | -24.96 Million USD | 50.53% |
| 2023 FY | -32.27 Million USD | -27.08% |
| 2023 Q1 | -50.47 Million USD | -98.74% |
| 2023 Q4 | -32.27 Million USD | -76.47% |
| 2022 Q4 | -25.39 Million USD | -69.82% |
| 2022 FY | -25.39 Million USD | 29.65% |
| 2022 Q2 | -24.39 Million USD | -7.68% |
| 2022 Q1 | -22.65 Million USD | 37.26% |
| 2022 Q3 | -14.95 Million USD | 38.68% |
| 2021 FY | -36.1 Million USD | 10.54% |
| 2021 Q1 | -66.17 Million USD | -63.99% |
| 2021 Q2 | -40.66 Million USD | 38.55% |
| 2021 Q3 | -69.1 Million USD | -69.92% |
| 2021 Q4 | -36.1 Million USD | 47.76% |
| 2020 Q4 | -40.35 Million USD | -181.36% |
| 2020 Q3 | -14.34 Million USD | 77.93% |
| 2020 FY | -40.35 Million USD | -432.74% |
| 2020 Q1 | -18.93 Million USD | -149.98% |
| 2020 Q2 | -64.98 Million USD | -243.19% |
| 2019 FY | -7.57 Million USD | 61.71% |
| 2019 Q2 | -15.33 Million USD | 41.68% |
| 2019 Q1 | -26.3 Million USD | -32.94% |
| 2019 Q3 | -12.85 Million USD | 16.22% |
| 2019 Q4 | -7.57 Million USD | 41.06% |
| 2018 Q1 | -39.82 Million USD | -18.1% |
| 2018 Q3 | -32.82 Million USD | 25.22% |
| 2018 Q4 | -19.78 Million USD | 39.73% |
| 2018 FY | -19.78 Million USD | 41.33% |
| 2018 Q2 | -43.89 Million USD | -10.22% |
| 2017 Q4 | -33.72 Million USD | 38.39% |
| 2017 FY | -33.72 Million USD | 20.58% |
| 2017 Q2 | -66.16 Million USD | -55.69% |
| 2017 Q1 | -42.49 Million USD | -0.08% |
| 2017 Q3 | -54.73 Million USD | 17.27% |
| 2016 Q4 | -42.46 Million USD | -55.17% |
| 2016 Q2 | -28.12 Million USD | 55.38% |
| 2016 Q1 | -63.02 Million USD | 6.89% |
| 2016 FY | -42.46 Million USD | 37.27% |
| 2016 Q3 | -27.36 Million USD | 2.69% |
| 2015 Q1 | -119.51 Million USD | -370.01% |
| 2015 FY | -67.69 Million USD | -166.2% |
| 2015 Q2 | -81.58 Million USD | 31.74% |
| 2015 Q3 | -66.79 Million USD | 18.13% |
| 2015 Q4 | -67.69 Million USD | -1.35% |
| 2014 Q2 | -40.79 Million USD | 28.3% |
| 2014 Q1 | -56.9 Million USD | 66.41% |
| 2014 Q4 | -25.42 Million USD | 21.82% |
| 2014 FY | -25.42 Million USD | 84.99% |
| 2014 Q3 | -32.52 Million USD | 20.28% |
| 2013 Q3 | -14.19 Million USD | 44.23% |
| 2013 Q2 | -25.45 Million USD | 61.18% |
| 2013 Q1 | -65.57 Million USD | -383.6% |
| 2013 Q4 | -169.4 Million USD | -1093.14% |
| 2013 FY | -169.4 Million USD | -1149.37% |
| 2012 FY | -13.55 Million USD | -491.43% |
| 2012 Q4 | -13.55 Million USD | -33.35% |
| 2012 Q3 | -10.16 Million USD | -135.04% |
| 2012 Q1 | -7.21 Million USD | -308.23% |
| 2012 Q2 | -4.32 Million USD | 40.02% |
| 2011 Q4 | 3.46 Million USD | 72.42% |
| 2011 Q1 | 4.89 Million USD | 143.32% |
| 2011 Q2 | 4.79 Million USD | -1.98% |
| 2011 Q3 | 2 Million USD | -58.08% |
| 2011 FY | 3.46 Million USD | 130.69% |
| 2010 Q2 | -1.93 Million USD | 93.19% |
| 2010 Q4 | -11.28 Million USD | -424.53% |
| 2010 Q3 | 3.47 Million USD | 279.65% |
| 2010 Q1 | -28.41 Million USD | 34.17% |
| 2010 FY | -11.28 Million USD | 73.85% |
| 2009 Q2 | -31.41 Million USD | 19.44% |
| 2009 Q1 | -38.99 Million USD | 9.88% |
| 2009 Q3 | -25.75 Million USD | 18.01% |
| 2009 FY | -43.16 Million USD | 0.25% |
| 2009 Q4 | -43.16 Million USD | -67.58% |
| 2008 Q3 | -41.74 Million USD | 18.73% |
| 2008 Q1 | -10.34 Million USD | 1.34% |
| 2008 Q2 | -51.36 Million USD | -396.37% |
| 2008 FY | -43.27 Million USD | -312.5% |
| 2008 Q4 | -43.27 Million USD | -3.66% |
| 2007 Q1 | -27.51 Million USD | 24.15% |
| 2007 Q2 | -25.33 Million USD | 7.91% |
| 2007 Q3 | -19.73 Million USD | 22.08% |
| 2007 Q4 | -10.48 Million USD | 46.86% |
| 2007 FY | -10.48 Million USD | 71.08% |
| 2006 Q4 | -36.26 Million USD | 22.31% |
| 2006 Q3 | -46.68 Million USD | 12.69% |
| 2006 Q1 | -57.54 Million USD | -148.0% |
| 2006 Q2 | -53.46 Million USD | 7.08% |
| 2006 FY | -36.26 Million USD | -56.32% |
| 2005 Q1 | -25.2 Million USD | 20.58% |
| 2005 FY | -23.2 Million USD | 21.72% |
| 2005 Q4 | -23.2 Million USD | -14.87% |
| 2005 Q3 | -20.19 Million USD | 18.97% |
| 2005 Q2 | -24.92 Million USD | 1.11% |
| 2004 Q1 | -41.16 Million USD | -103.26% |
| 2004 FY | -29.64 Million USD | -46.37% |
| 2004 Q4 | -31.74 Million USD | 9.12% |
| 2004 Q3 | -34.92 Million USD | 11.28% |
| 2004 Q2 | -39.37 Million USD | 4.35% |
| 2003 Q3 | -23.49 Million USD | -38.36% |
| 2003 FY | -20.25 Million USD | 19.22% |
| 2003 Q4 | -20.25 Million USD | 13.82% |
| 2003 Q1 | -19.75 Million USD | 21.22% |
| 2003 Q2 | -16.98 Million USD | 14.01% |
| 2002 Q3 | -26.31 Million USD | 16.91% |
| 2002 FY | -25.07 Million USD | 41.24% |
| 2002 Q1 | -37.05 Million USD | 13.15% |
| 2002 Q2 | -31.66 Million USD | 14.54% |
| 2002 Q4 | -25.07 Million USD | 4.72% |
| 2001 Q3 | -34.68 Million USD | 14.52% |
| 2001 Q2 | -40.58 Million USD | 9.63% |
| 2001 Q1 | -44.9 Million USD | 10.01% |
| 2001 Q4 | -42.66 Million USD | -23.0% |
| 2001 FY | -42.66 Million USD | 14.5% |
| 2000 Q4 | -49.9 Million USD | -3.61% |
| 2000 Q3 | -48.16 Million USD | -207.85% |
| 2000 Q2 | -15.64 Million USD | 14.37% |
| 2000 Q1 | -18.27 Million USD | -39.95% |
| 2000 FY | -49.9 Million USD | -282.22% |
| 1999 FY | -13.05 Million USD | -78.85% |
| 1999 Q4 | -13.05 Million USD | 9.33% |
| 1999 Q3 | -14.4 Million USD | -100.0% |
| 1999 Q2 | -7.2 Million USD | 24.21% |
| 1999 Q1 | -9.5 Million USD | -30.14% |
| 1998 Q1 | -6.6 Million USD | -37.5% |
| 1998 Q4 | -7.3 Million USD | -30.36% |
| 1998 FY | -7.3 Million USD | -52.08% |
| 1998 Q3 | -5.6 Million USD | -55.56% |
| 1998 Q2 | -3.6 Million USD | 45.45% |
| 1997 Q1 | -12.2 Million USD | 3.17% |
| 1997 Q4 | -4.8 Million USD | 43.53% |
| 1997 Q2 | -10.7 Million USD | 12.3% |
| 1997 Q3 | -8.5 Million USD | 20.56% |
| 1997 FY | -4.8 Million USD | 61.9% |
| 1996 Q2 | -6.5 Million USD | 29.35% |
| 1996 FY | -12.6 Million USD | -4.13% |
| 1996 Q1 | -9.2 Million USD | 23.97% |
| 1996 Q4 | -12.6 Million USD | 11.27% |
| 1996 Q3 | -14.2 Million USD | -118.46% |
| 1995 Q2 | -10.3 Million USD | 16.94% |
| 1995 FY | -12.1 Million USD | -70.42% |
| 1995 Q4 | -12.1 Million USD | -101.67% |
| 1995 Q3 | -6 Million USD | 41.75% |
| 1995 Q1 | -12.4 Million USD | -74.65% |
| 1994 Q4 | -7.1 Million USD | 60.99% |
| 1994 Q3 | -18.2 Million USD | 10.34% |
| 1994 Q2 | -20.3 Million USD | 15.06% |
| 1994 FY | -7.1 Million USD | 74.46% |
| 1994 Q1 | -23.9 Million USD | 14.03% |
| 1993 Q3 | -12.1 Million USD | 11.03% |
| 1993 Q1 | -15.6 Million USD | 0.0% |
| 1993 FY | -27.8 Million USD | -742.42% |
| 1993 Q2 | -13.6 Million USD | 12.82% |
| 1993 Q4 | -27.8 Million USD | -129.75% |
| 1992 Q3 | -19 Million USD | 8.21% |
| 1992 Q1 | -22.1 Million USD | 4.33% |
| 1992 Q2 | -20.7 Million USD | 6.33% |
| 1992 FY | -3.3 Million USD | 62.07% |
| 1991 Q3 | -24 Million USD | 5.88% |
| 1991 Q4 | -23.1 Million USD | 3.75% |
| 1991 FY | -8.7 Million USD | 23.01% |
| 1991 Q1 | -8.7 Million USD | -7.41% |
| 1991 Q2 | -25.5 Million USD | -193.1% |
| 1990 Q3 | -9.3 Million USD | 15.45% |
| 1990 FY | -11.3 Million USD | -17.71% |
| 1990 Q4 | -8.1 Million USD | 12.9% |
| 1990 Q2 | -11 Million USD | 2.65% |
| 1990 Q1 | -11.3 Million USD | -56.94% |
| 1989 FY | -9.6 Million USD | 11.11% |
| 1989 Q4 | -7.2 Million USD | 0.0% |
| 1989 Q1 | -9.6 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 42.31% |
| Alkermes plc | -166.73 Million USD | 80.645% |
| Agenus Inc. | 274.13 Million USD | 111.772% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 101.726% |
| Aptorum Group Limited | 1.35 Million USD | 2478.107% |
| Ardelyx, Inc. | 34.51 Million USD | 193.51% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 854.019% |
| Bicycle Therapeutics plc | -481.46 Million USD | 93.297% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 189.24% |
| ChromaDex Corporation | -24.04 Million USD | -34.198% |
| Chimerix, Inc. | -25.51 Million USD | -26.473% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 563.141% |
| Caribou Biosciences, Inc. | -23.67 Million USD | -36.301% |
| CRISPR Therapeutics AG | -150.84 Million USD | 78.606% |
| Precision BioSciences, Inc. | -85.41 Million USD | 62.215% |
| Dyadic International, Inc. | -6.37 Million USD | -405.981% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | -102.548% |
| Fortress Biotech, Inc. | 7.66 Million USD | 521.031% |
| Lantern Pharma Inc. | -21.7 Million USD | -48.696% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 70.804% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | -277.752% |
| Incyte Corporation | -3.17 Billion USD | 98.984% |
| IO Biotech, Inc. | -140.69 Million USD | 77.063% |
| Jaguar Health, Inc. | 29.39 Million USD | 209.802% |
| Novavax, Inc. | -298.29 Million USD | 89.181% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 704.684% |
| Opthea Limited | 28.15 Million USD | 214.613% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | -92.221% |
| ContextLogic Inc. | -232 Million USD | 86.09% |
| MiMedx Group, Inc. | -33.9 Million USD | 4.805% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 416.547% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | -1292.819% |
| NextCure, Inc. | -6.47 Million USD | -398.255% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 36.096% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | -405.91% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 365.323% |
| Vaxcyte, Inc. | -368.22 Million USD | 91.236% |
| PDS Biotechnology Corporation | -32.7 Million USD | 1.336% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 286.781% |
| Pharming Group N.V. | 109.8 Million USD | 129.391% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | -85.514% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 81.583% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -74.256% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | -74.256% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -354.535% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | -450.717% |
| Acelyrin, Inc. | -216.9 Million USD | 85.121% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | -475.231% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | -1771.926% |
| Summit Therapeutics Inc. | 34.67 Million USD | 193.073% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | -374.379% |
| Senti Biosciences, Inc. | 1.74 Million USD | 1954.713% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 82.519% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 58.332% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | -432.366% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 32446.721% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 5238.854% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 72.428% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 80.817% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 129.108% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | -324.855% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 75.005% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 568.077% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 86.684% |
| Immix Biopharma, Inc. | -17.5 Million USD | -84.308% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 89.81% |
| MEI Pharma, Inc. | -3.7 Million USD | -771.039% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 357.949% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 119.953% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 216.116% |
| Fortress Biotech, Inc. | 7.66 Million USD | 521.031% |
| Precigen, Inc. | -481 Thousand USD | -6609.356% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 329.188% |
| AlloVir, Inc. | -62.69 Million USD | 48.523% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 41.971% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 152.334% |
| ImmuCell Corporation | 10.99 Million USD | 393.634% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 79.064% |
| Onconetix, Inc. | 5.33 Million USD | 705.315% |
| PureTech Health plc | -167.19 Million USD | 80.698% |
| VYNE Therapeutics Inc. | -30.46 Million USD | -5.949% |
| Elevation Oncology, Inc. | -19.11 Million USD | -68.804% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | -557.405% |
| Seer, Inc. | -4.24 Million USD | -661.132% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | -34.26% |
| Innoviva, Inc. | 255.56 Million USD | 112.628% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 42.231% |
| ESSA Pharma Inc. | -33.62 Million USD | 4.014% |
| GlycoMimetics, Inc. | -40.98 Million USD | 21.258% |
| GT Biopharma, Inc. | -1.02 Million USD | -3060.823% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 52.389% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 152.683% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 75.931% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | -132.91% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | -11.776% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -42738.559% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | -4.569% |
| Aptose Biosciences Inc. | -8.19 Million USD | -293.808% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | -931.378% |
| Soligenix, Inc. | -4.95 Million USD | -551.749% |
| Century Therapeutics, Inc. | 847 Thousand USD | 3910.153% |
| Kura Oncology, Inc. | -20.11 Million USD | -60.414% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 21.145% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | -284.282% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 1871.537% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | -909.446% |
| Autolus Therapeutics plc | -186.59 Million USD | 82.705% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 34.545% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 88.299% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 194.175% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 119.634% |
| GRI Bio, Inc. | -1.79 Million USD | -1698.885% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | -259.255% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 2.962% |
| IGM Biosciences, Inc. | -72.6 Million USD | 55.552% |
| INmune Bio, Inc. | -25.41 Million USD | -27.0% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 121.379% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 36.296% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -98.605% |
| Entero Therapeutics, Inc. | -2.88 Million USD | -1018.642% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 184.893% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 21.641% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 201.214% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 108.539% |
| Verastem, Inc. | -37.27 Million USD | 13.429% |
| Abeona Therapeutics Inc. | -9.07 Million USD | -255.693% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 37.773% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | -113.228% |
| Histogen Inc. | -7.48 Million USD | -331.04% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | -49.36% |
| Surrozen, Inc. | -32.66 Million USD | 1.2% |
| Organovo Holdings, Inc. | -1.5 Million USD | -2041.473% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -667.743% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 270.209% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 1333.639% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 876.516% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | -285.055% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 25.712% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | -121.392% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 89.813% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -4369.435% |
| Apollomics, Inc. | -27.39 Million USD | -17.803% |
| Amarin Corporation plc | -191.04 Million USD | 83.107% |
| Mesoblast Limited | 55.96 Million USD | 157.667% |
| Turnstone Biologics Corp. | -14.58 Million USD | -121.284% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | -27.598% |
| Synaptogenix, Inc. | -28.66 Million USD | -12.597% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -3347.863% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 166.223% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -3643.465% |
| Monopar Therapeutics Inc. | -7.26 Million USD | -344.146% |
| Exelixis, Inc. | -73.05 Million USD | 55.822% |
| Better Therapeutics, Inc. | -860 Thousand USD | -3652.558% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | -34.394% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 86.63% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 4484.389% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | -333.872% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 2673.525% |
| Gritstone bio, Inc. | 39.49 Million USD | 181.722% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 61.627% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | -1126.075% |
| Avid Bioservices, Inc. | 169.72 Million USD | 119.014% |
| Insmed Incorporated | 721.62 Million USD | 104.472% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | -253.027% |
| MediWound Ltd. | -5.32 Million USD | -506.389% |
| OmniAb, Inc. | 9.2 Million USD | 450.668% |
| Alector, Inc. | -35.63 Million USD | 9.442% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 137.538% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | -554.87% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 343.765% |
| Zai Lab Limited | -775 Million USD | 95.836% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 109.476% |
| Aura Biosciences, Inc. | -21.52 Million USD | -49.928% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 60.873% |
| Immunic, Inc. | -45.34 Million USD | 28.822% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 83.297% |
| Veracyte, Inc. | -203.82 Million USD | 84.167% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 105.056% |
| FibroGen, Inc. | 56.76 Million USD | 156.85% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 462.403% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | -1041.53% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | -1458.772% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.703% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | -865.938% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 80.555% |
| TG Therapeutics, Inc. | 17.86 Million USD | 280.674% |
| Galecto, Inc. | -21.21 Million USD | -52.112% |
| Calithera Biosciences, Inc. | -23.78 Million USD | -35.682% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 102.056% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | -31.873% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | -180.455% |
| XBiotech Inc. | -200.02 Million USD | 83.866% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 61.627% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 812.721% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 8.482% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 58.207% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 667.071% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 81.063% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 65.064% |
| Vaxxinity, Inc. | 10.13 Million USD | 418.516% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 104.383% |
| Gain Therapeutics, Inc. | -10.76 Million USD | -199.715% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 51.07% |
| NexImmune, Inc. | -3.13 Million USD | -929.856% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | -834.696% |
| Marker Therapeutics, Inc. | -15.11 Million USD | -113.56% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -19.085% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | -259.534% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -25805.679% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 20.457% |
| Ainos, Inc. | 4.07 Million USD | 891.382% |
| Pluri Inc. | 22.82 Million USD | 241.364% |
| Prothena Corporation plc | -608.34 Million USD | 94.695% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 72.825% |
| Celularity Inc. | 65.19 Million USD | 149.505% |
| Rallybio Corporation | -24.1 Million USD | -33.898% |
| Cue Biopharma, Inc. | -33.81 Million USD | 4.574% |
| MeiraGTx Holdings plc | -40.3 Million USD | 19.925% |
| Omeros Corporation | 331.17 Million USD | 109.745% |
| Humacyte, Inc. | -22.48 Million USD | -43.52% |
| Immunocore Holdings plc | -358.59 Million USD | 91.0% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | -31.32% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | -4.437% |
| Blueprint Medicines Corporation | 702.83 Million USD | 104.592% |
| CalciMedica, Inc. | -5.53 Million USD | -483.58% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 82.854% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | -215.958% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 19.395% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 2.95% |
| Pulmatrix, Inc. | -10.41 Million USD | -209.801% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | -439.936% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 15.39% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 71.031% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 46.163% |
| Cytokinetics, Incorporated | 642.37 Million USD | 105.024% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | -454.216% |
| Nutriband Inc. | -251.65 Thousand USD | -12723.804% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 5.413% |
| Vor Biopharma Inc. | 4.3 Million USD | 850.512% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.465% |
| Evogene Ltd. | -19.63 Million USD | -64.368% |
| ProKidney Corp. | -56.23 Million USD | 42.613% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 33.695% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | -249.37% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 102.366% |
| CorMedix Inc. | -43.05 Million USD | 25.04% |
| BioLineRx Ltd. | 7.33 Million USD | 539.913% |
| Tango Therapeutics, Inc. | -27.46 Million USD | -17.502% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 169.933% |
| Atai Life Sciences N.V. | -28.55 Million USD | -13.005% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 1546.832% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | -41.445% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 281.968% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 57.013% |
| MediciNova, Inc. | -50.78 Million USD | 36.452% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 59.048% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -143362.992% |
| GeoVax Labs, Inc. | -6.45 Million USD | -400.14% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 83.85% |
| Biomea Fusion, Inc. | -166.57 Million USD | 80.626% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 81.968% |
| Mereo BioPharma Group plc | -51.46 Million USD | 37.298% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 65.974% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 89.014% |
| Absci Corporation | -72.59 Million USD | 55.547% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 806.789% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 86.234% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 65.745% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 66.277% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 17.406% |
| Allakos Inc. | -24.97 Million USD | -29.217% |
| Imunon, Inc. | -4.21 Million USD | -665.855% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | -118.912% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 76.165% |
| BioAtla, Inc. | -109.01 Million USD | 70.396% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 4484.389% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -3336.848% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 369.697% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | -52.205% |
| XOMA Corporation | -29 Million USD | -11.283% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | -94.879% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -257.941% |
| aTyr Pharma, Inc. | -7.44 Million USD | -333.239% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 74.107% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 84.497% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 60.538% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 65.21% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -3656.122% |
| Akari Therapeutics, Plc | -3.84 Million USD | -739.324% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 2088.551% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 102.337% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -2616.19% |
| UroGen Pharma Ltd. | 4.39 Million USD | 834.958% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 128.438% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 44945.891% |
| Orgenesis Inc. | 21.78 Million USD | 248.145% |
| Entera Bio Ltd. | -10.62 Million USD | -203.622% |
| GH Research PLC | -78.07 Million USD | 58.666% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | -44.795% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | -21.055% |
| Xencor, Inc. | 29.64 Million USD | 208.865% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | -1538.329% |
| Replimune Group, Inc. | 1.41 Million USD | 2385.552% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -13077.193% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 74.472% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -2616.19% |
| Portage Biotech Inc. | -4.98 Million USD | -547.902% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -143362.992% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 51.193% |
| OncoCyte Corporation | -6.56 Million USD | -391.726% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 3696.115% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | -608.396% |
| Purple Biotech Ltd. | -14.13 Million USD | -128.264% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | -35.848% |
| scPharmaceuticals Inc. | -6.54 Million USD | -393.079% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | -93.336% |
| HilleVax, Inc. | -165.48 Million USD | 80.499% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | -1171.552% |
| Tharimmune, Inc. | -10.93 Million USD | -195.116% |
| Genprex, Inc. | -6.73 Million USD | -378.982% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 91.25% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 63.518% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -2203.498% |
| Virios Therapeutics, Inc. | -3.31 Million USD | -872.943% |
| OKYO Pharma Limited | -826.84 Thousand USD | -3803.015% |
| Savara Inc. | 153 Thousand USD | 21192.81% |
| Curis, Inc. | -23.88 Million USD | -35.103% |
| Daré Bioscience, Inc. | -5.15 Million USD | -525.68% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -4058.699% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | -419.845% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 2823.376% |
| BeiGene, Ltd. | -2.25 Billion USD | 98.568% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 361.555% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 94.694% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 82.611% |
| Erasca, Inc. | -37.21 Million USD | 13.285% |
| bluebird bio, Inc. | 108.57 Million USD | 129.724% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -2405.798% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 108.521% |
| DBV Technologies S.A. | -126.98 Million USD | 74.586% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -2405.798% |
| Moderna, Inc. | -2.9 Billion USD | 98.89% |
| Vincerx Pharma, Inc. | -10.35 Million USD | -211.747% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | -196.945% |
| Molecular Templates, Inc. | 707 Thousand USD | 4664.639% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | -2.872% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 109.311% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 60.674% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 64.818% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 6.121% |
| MacroGenics, Inc. | -66.98 Million USD | 51.822% |
| RenovoRx, Inc. | -1.17 Million USD | -2651.236% |
| Adicet Bio, Inc. | -138.78 Million USD | 76.747% |
| Prime Medicine, Inc. | -27.94 Million USD | -15.501% |
| Aditxt, Inc. | 18.12 Million USD | 278.093% |
| Adagene Inc. | -87.62 Million USD | 63.171% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -674.758% |
| Quantum-Si incorporated | -118.55 Million USD | 72.779% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 189.632% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | -331.779% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 33.472% |
| SciSparc Ltd. | -2.06 Million USD | -1462.809% |
| Vericel Corporation | 1.27 Million USD | 2627.173% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -169.119% |
| Minerva Neurosciences, Inc. | 41 Million USD | 178.704% |
| Generation Bio Co. | 31.44 Million USD | 202.62% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 81.597% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | -4.362% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 127.679% |
| Invivyd, Inc. | -198.47 Million USD | 83.74% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 64.249% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | -1245.963% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 54.412% |
| Artelo Biosciences, Inc. | -6.82 Million USD | -372.85% |
| 2seventy bio, Inc. | 181.71 Million USD | 117.76% |
| ADMA Biologics, Inc. | 90.06 Million USD | 135.832% |
| Clene Inc. | 3.34 Million USD | 1066.228% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | -255.313% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | -50.026% |
| GeoVax Labs, Inc. | -6.45 Million USD | -400.14% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 90.622% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | -24.125% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 118.164% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | -688.744% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 745.182% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | -519.543% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 75.233% |
| Evaxion Biotech A/S | 5.28 Million USD | 710.421% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 71.331% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 75.416% |
| Trevena, Inc. | 2.25 Million USD | 1529.229% |
| Surrozen, Inc. | -32.66 Million USD | 1.2% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 37.348% |
| Cingulate Inc. | 3.08 Million USD | 1146.88% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | -998.808% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 549.033% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | -247.338% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 59.316% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 75.45% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 69.423% |
| Clearmind Medicine Inc. | -3.94 Million USD | -718.538% |
| Kronos Bio, Inc. | -36.05 Million USD | 10.49% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 442.991% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 2313.25% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 40.519% |
| Statera Biopharma, Inc. | 14.41 Million USD | 323.856% |
| ImmunityBio, Inc. | 618.22 Million USD | 105.22% |
| Korro Bio, Inc. | -132.94 Million USD | 75.725% |
| Kineta, Inc. | -4.54 Million USD | -610.68% |
| BioVie Inc. | -17.73 Million USD | -81.995% |
| Codexis, Inc. | -43.27 Million USD | 25.419% |
| Celularity Inc. | 65.19 Million USD | 149.505% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | -918.365% |
| Celcuity Inc. | 6.78 Million USD | 575.742% |
| Virax Biolabs Group Limited | -3.36 Million USD | -859.065% |
| Cibus, Inc. | -8.07 Million USD | -299.505% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | -663.112% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 806.171% |
| IN8bio, Inc. | -16.38 Million USD | -96.913% |
| Kodiak Sciences Inc. | -103.87 Million USD | 68.932% |
| Annexon, Inc. | -193.75 Million USD | 83.344% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 89744.444% |
| Assembly Biosciences, Inc. | -17.49 Million USD | -84.422% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | -818.645% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 103.061% |
| Eyenovia, Inc. | 1.25 Million USD | 2663.911% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 219.948% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -895.128% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 2.933% |
| Arcellx, Inc. | -296.95 Million USD | 89.132% |
| Cardiff Oncology, Inc. | -19.5 Million USD | -65.447% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 45.186% |
| Regulus Therapeutics Inc. | -20.72 Million USD | -55.7% |
| Moolec Science SA | 117.61 Thousand USD | 27538.444% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 15.956% |
| Geron Corporation | 14.76 Million USD | 318.63% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 14.89% |
| Royalty Pharma plc | 5.65 Billion USD | 100.57% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 77.18% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | -361.726% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | -501.769% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 77.068% |
| Humacyte, Inc. | -22.48 Million USD | -43.52% |
| Structure Therapeutics Inc. | -124.33 Million USD | 74.045% |
| 89bio, Inc. | -289.05 Million USD | 88.835% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | -27.85% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | -1709.983% |
| Genelux Corporation | -6.89 Million USD | -367.778% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | -3.905% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 138.603% |
| Notable Labs, Ltd. | -9.77 Million USD | -230.115% |
| Liquidia Corporation | -80.17 Million USD | 59.749% |
| Mustang Bio, Inc. | -3.73 Million USD | -763.812% |
| Immunovant, Inc. | -635.22 Million USD | 94.92% |
| Quantum-Si incorporated | -118.55 Million USD | 72.779% |
| Arbutus Biopharma Corporation | -17.56 Million USD | -83.739% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | -678.952% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 502.043% |
| Acasti Pharma Inc. | -23 Million USD | -40.283% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | -858.414% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | -98.605% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 76.57% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | -935.566% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | -45.16% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | -73.795% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 80.936% |
| PepGen Inc. | -60.67 Million USD | 46.807% |
| Moleculin Biotech, Inc. | -22.97 Million USD | -40.46% |
| United Therapeutics Corporation | -507.7 Million USD | 93.643% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | -68.734% |
| Solid Biosciences Inc. | -47.75 Million USD | 32.415% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -3643.465% |
| Immuneering Corporation | -54.94 Million USD | 41.263% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | -667.743% |
| Silo Pharma, Inc. | -3.52 Million USD | -815.697% |
| Belite Bio, Inc | -87.27 Million USD | 63.021% |
| XOMA Corporation | -29 Million USD | -11.283% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 54.352% |
| Bionomics Limited | 227 Million USD | 114.216% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 72.247% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -1174.062% |
| uniQure N.V. | -102.95 Million USD | 68.653% |
| Cassava Sciences, Inc. | -121.13 Million USD | 73.359% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | -674.758% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 178.806% |
| Forte Biosciences, Inc. | -11.96 Million USD | -169.81% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | -942.984% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 30545.283% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | -895.128% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 462.403% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | -335.167% |
| Altimmune, Inc. | -134.48 Million USD | 76.004% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 116.294% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | -1174.062% |
| Compugen Ltd. | -12.9 Million USD | -150.093% |
| Peak Bio, Inc. | 10.34 Million USD | 412.104% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -11303.534% |
| Benitec Biopharma Inc. | -50.58 Million USD | 36.199% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 69.07% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 264.276% |
| Zura Bio Limited | -99.8 Million USD | 67.665% |
| PolyPid Ltd. | 6.17 Million USD | 623.047% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 143.54% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 264.276% |
| Instil Bio, Inc. | 75.35 Million USD | 142.825% |
| argenx SE | -2.02 Billion USD | 98.409% |
| Immunome, Inc. | -97.02 Million USD | 66.74% |
| Compass Therapeutics, Inc. | -22.49 Million USD | -43.463% |
| Verona Pharma plc | -220.44 Million USD | 85.36% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 55.017% |
| Shattuck Labs, Inc. | -121.42 Million USD | 73.422% |
| CervoMed Inc. | -7.79 Million USD | -314.123% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 82.603% |
| Plus Therapeutics, Inc. | -4.37 Million USD | -637.983% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 75.503% |
| Moolec Science SA | 117.61 Thousand USD | 27538.444% |
| Enveric Biosciences, Inc. | -2.28 Million USD | -1310.504% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 302.989% |
| AnaptysBio, Inc. | -18.15 Million USD | -77.797% |
| Design Therapeutics, Inc. | -18.15 Million USD | -77.807% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 54.147% |
| NeurAxis, Inc. | 145.7 Thousand USD | 22249.623% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 387.322% |
| Lumos Pharma, Inc. | -28.49 Million USD | -13.263% |
| Achilles Therapeutics plc | -126.92 Million USD | 74.574% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 55.017% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -4821.538% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | -55.349% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 2313.25% |
| Nutriband Inc. | -251.65 Thousand USD | -12723.804% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | -145.023% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | -333.763% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 109.486% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 235.968% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 92.788% |
| Palisade Bio, Inc. | -12.06 Million USD | -167.529% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 77.0% |
| Beam Therapeutics Inc. | -262.72 Million USD | 87.716% |
| Neurogene Inc. | -131.95 Million USD | 75.543% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 247.928% |
| AEON Biopharma, Inc. | -4.88 Million USD | -561.311% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 91.444% |
| Sesen Bio, Inc. | -112.55 Million USD | 71.327% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 67.683% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | -1274.568% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 17.306% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 61.25% |
| Athira Pharma, Inc. | -88.99 Million USD | 63.739% |
| Vaccinex, Inc. | -1.28 Million USD | -2405.59% |
| HCW Biologics Inc. | 2.85 Million USD | 1229.705% |
| XOMA Corporation | -29 Million USD | -11.283% |
| Nektar Therapeutics | 210.24 Million USD | 115.35% |
| Arvinas, Inc. | -313.8 Million USD | 89.716% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 2088.551% |
| Merus N.V. | -192.88 Million USD | 83.269% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 153.8% |
| Quince Therapeutics, Inc. | -6.93 Million USD | -365.148% |
| Rezolute, Inc. | -68.16 Million USD | 52.658% |
| Clene Inc. | 3.34 Million USD | 1066.228% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | -144.726% |
| BeyondSpring Inc. | -13.75 Million USD | -134.62% |
| Synlogic, Inc. | -6.68 Million USD | -382.752% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 2945.855% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | -281.691% |
| Peak Bio, Inc. | 10.34 Million USD | 412.104% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 60.844% |
| Krystal Biotech, Inc. | -350.23 Million USD | 90.786% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 126.0% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 80.904% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | -922.19% |
| MannKind Corporation | 143.89 Million USD | 122.427% |
| Ikena Oncology, Inc. | -109.15 Million USD | 70.435% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | -326.258% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 2.502% |
| Gossamer Bio, Inc. | 180.35 Million USD | 117.894% |
| CohBar, Inc. | -5.93 Million USD | -444.149% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | -8.485% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 806.789% |
| Legend Biotech Corporation | -949.39 Million USD | 96.601% |
| Mural Oncology plc | -255.84 Million USD | 87.386% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 200.177% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | -585.087% |
| Disc Medicine, Inc. | -358.28 Million USD | 90.993% |
| Champions Oncology, Inc. | 4.81 Million USD | 770.657% |
| REGENXBIO Inc. | 54.76 Million USD | 158.925% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -11901.175% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 78.631% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | -258.1% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 60.001% |
| Vaxart, Inc. | -8.24 Million USD | -291.603% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 35.687% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 74.622% |
| Cellectis S.A. | -43.85 Million USD | 26.412% |
| Longeveron Inc. | -2.9 Million USD | -1009.766% |
| Repare Therapeutics Inc. | -107.85 Million USD | 70.079% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 103.333% |
| Inozyme Pharma, Inc. | 12 Million USD | 368.844% |
| Revolution Medicines, Inc. | -608.2 Million USD | 94.694% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -2523.74% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 87.827% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 78.496% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | -106.25% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -4261.081% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.663% |
| Denali Therapeutics Inc. | -74.86 Million USD | 56.893% |
| Revelation Biosciences, Inc. | -11.99 Million USD | -169.119% |
| Veru Inc. | 4.77 Million USD | 775.151% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | -186.964% |
| Cingulate Inc. | 3.08 Million USD | 1146.88% |
| Passage Bio, Inc. | 4.58 Million USD | 803.86% |
| Context Therapeutics Inc. | -14.44 Million USD | -123.338% |
| Exicure, Inc. | 5.84 Million USD | 651.752% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 85.992% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 18.443% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 305.672% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 45.135% |
| Nuvalent, Inc. | -335.38 Million USD | 90.378% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 1960.764% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 56.671% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | -263.015% |
| OmniAb, Inc. | 9.2 Million USD | 450.668% |
| Anew Medical, Inc. | 1.43 Million USD | 2352.9% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 297.0% |
| Lipocine Inc. | -4.75 Million USD | -578.754% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 70.616% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 311.884% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 36.296% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 229.648% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | -380.167% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 50.975% |
| Ocugen, Inc. | -32.52 Million USD | 0.766% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 62.288% |
| Q32 Bio Inc. | -37.94 Million USD | 14.957% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -5038.854% |
| Alumis Inc. Common Stock | -13.52 Million USD | -138.539% |
| Equillium, Inc. | -22.39 Million USD | -44.123% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | -26.22% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 1.087% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -12917.365% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 124.076% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 1109.131% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 9925.813% |
| Dominari Holdings Inc. | 195 Thousand USD | 16649.744% |
| Edesa Biotech, Inc. | -5.26 Million USD | -512.731% |
| vTv Therapeutics Inc. | -8.91 Million USD | -261.915% |
| Bio-Techne Corporation | 267.74 Million USD | 112.053% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | -99.099% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 72.673% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | -284.053% |
| Candel Therapeutics, Inc. | -12.65 Million USD | -155.094% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 86.834% |
| Nkarta, Inc. | 57.29 Million USD | 156.322% |
| BioCardia, Inc. | 212 Thousand USD | 15322.642% |
| Iterum Therapeutics plc | 13.43 Million USD | 340.155% |